Evidence map›Paper›PMID 27864362›Full record

ArticleThe Journal of biological chemistry2016

Identification of Lysophosphatidic Acid Receptor 1 in Astroglial Cells as a Target for Glial Cell Line-derived Neurotrophic Factor Expression Induced by Antidepressants.

Naoto Kajitani, Kanako Miyano, Mami Okada-Tsuchioka, Hiromi Abe, Kei Itagaki, Kazue Hisaoka-Nakashima, Norimitsu Morioka, Yasuhito Uezono, Minoru Takebayashi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Generation of New Knock-Out Mouse Strains ofInternational journal of molecular sciences · 2025
    Article
  3. Article
  4. G protein-biased LPAR1 agonism of prototypic antidepressants: Implication in the identification of novel therapeutic target for depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder.The international journal of neuropsychopharmacology · 2019
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Naoto KajitaniFrom the Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure 737-0023.
Kanako Miyanothe Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045.
Mami Okada-TsuchiokaFrom the Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure 737-0023.
Hiromi AbeFrom the Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure 737-0023.
Kei ItagakiFrom the Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure 737-0023.
Kazue Hisaoka-Nakashimathe Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, and.
Norimitsu Moriokathe Department of Pharmacology, Hiroshima University Graduate School of Biomedical & Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, and.
Yasuhito Uezonothe Division of Cancer Pathophysiology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045.
Minoru TakebayashiFrom the Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization (NHO) Kure Medical Center and Chugoku Cancer Center, 3-1 Aoyama, Kure 737-0023, mtakebayashi@kure-nh.go.jp.
National Hospital Organization · JPHiroshima University · JPNational Cancer Research Institute · GBKure Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical and clinical evidence suggests that glial cell line-derived neurotrophic factor (GDNF) is important in the therapeutic effect of antidepressants. A previous study demonstrated that the tricyclic antidepressant amitriptyline induces Gα

Indexed as

AnimalsAnimals, NewbornAntidepressive AgentsAstrocytesCells, CulturedGene Expression RegulationGlial Cell Line-Derived Neurotrophic FactorGliomaNeuronsPhosphorylationRatsRats, WistarReceptors, Lysophosphatidic AcidRNA, Small InterferingSignal TransductionAntidepressive AgentsGdnf protein, ratGlial Cell Line-Derived Neurotrophic FactorLpar1 protein, ratReceptors, Lysophosphatidic AcidRNA, Small Interferingantidepressantsastrocytedepressiondrug actionglial cell line-derived neurotrophic factorG protein-coupled receptor (GPCR)lipid signalinglysophosphatidic acid receptor 1transactivation

Identifiers

PMID27864362
PMCPMC5207162
OpenAlexW2556750374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.